Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL J BORNE

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1588750178
CMS profile
343940
Location
JACKSON, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$61,874.33

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Compensation for serving as faculty or as a speaker for a medical education program $50,628.00 10
Travel and Lodging $7,284.12 19
Food and Beverage $2,072.21 35
Consulting Fee $1,890.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Apellis Pharmaceuticals, Inc. $61,069.37 45
Regeneron Healthcare Solutions, Inc. $340.79 10
ABBVIE INC. $204.62 5
Ocular Therapeutix, Inc. $175.80 2
Astellas Pharma US Inc $64.13 2
Genentech USA, Inc. $19.62 1

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL J BORNE

NPI 1588750178 · CMS profile ID 343940

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

JACKSON, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588750178?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL J BORNE, NPI 1588750178, CMS profile ID 343940. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588750178?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHAEL J BORNE, NPI 1588750178, CMS profile ID 343940. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588750178?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHAEL J BORNE, NPI 1588750178, CMS profile ID 343940, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1588750178?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $61,874.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Apellis Pharmaceuticals, Inc. $77.7502/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1253201166 CMS
Ocular Therapeutix, Inc. $25.8002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250232735 CMS
Apellis Pharmaceuticals, Inc. $6,426.0002/13/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1253201172 CMS
Apellis Pharmaceuticals, Inc. $275.8002/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1253201176 CMS
Regeneron Healthcare Solutions, Inc. $31.1402/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212877001 CMS
Apellis Pharmaceuticals, Inc. $55.1701/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253201160 CMS
Apellis Pharmaceuticals, Inc. $281.0701/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1253201162 CMS
Apellis Pharmaceuticals, Inc. $552.2601/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1253201164 CMS
Apellis Pharmaceuticals, Inc. $121.6701/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253201168 CMS
Apellis Pharmaceuticals, Inc. $311.3601/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1253201174 CMS
Apellis Pharmaceuticals, Inc. $5,670.0001/22/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1253201180 CMS
Apellis Pharmaceuticals, Inc. $34.2601/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253201158 CMS
Apellis Pharmaceuticals, Inc. $119.5801/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253201170 CMS
Apellis Pharmaceuticals, Inc. $201.9601/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1253201178 CMS
ABBVIE INC. $34.4701/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201541952 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,072.84 8
PY2020 $7,638.06 9
PY2021 $20,361.34 23
PY2022 $20,595.45 33
PY2023 $553.11 23
PY2024 $39,046.49 49
PY2025 $61,874.33 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $10,650.00 1
PY2025 Principal investigator $685,199.13 180
PY2024 Principal investigator $85,513.14 11
PY2023 Principal investigator $21,303.49 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

181 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $2,754.00 12/29/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235207
Principal investigator 1 Ocular Therapeutix, Inc. $4,266.00 12/24/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235195
Principal investigator 1 Ocular Therapeutix, Inc. $236.04 12/24/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235199
Principal investigator 1 Ocular Therapeutix, Inc. $9,284.00 12/24/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235203
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $255.00 12/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815756
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 12/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815758
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,025.00 12/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815760
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $36,216.00 12/22/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815754
Principal investigator 1 Ocular Therapeutix, Inc. $3,580.00 12/19/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235190
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 12/17/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775087
Principal investigator 1 Boehringer Ingelheim International GmbH $20.88 12/17/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775089
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 12/17/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775091
Principal investigator 1 Ocular Therapeutix, Inc. $5,266.00 12/17/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235186
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
Mississippi Retina Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234946
Principal investigator 1 Ocular Therapeutix, Inc. $2,472.06 12/12/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235182
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,437.15 12/11/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815750
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,437.15 12/11/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815752
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $203.00 12/08/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815746
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $510.00 12/08/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815748
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775083
Principal investigator 1 Ocular Therapeutix, Inc. $22,572.00 12/01/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235177
Principal investigator 1 Ocular Therapeutix, Inc. $170.10 11/26/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235169
Principal investigator 1 Ocular Therapeutix, Inc. $17,789.00 11/26/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235173
Principal investigator 1 Astellas Pharma Global Development $575.00 11/24/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183841
Principal investigator 1 Astellas Pharma Global Development $575.00 11/24/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183843
Principal investigator 1 Astellas Pharma Global Development $575.00 11/24/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183851
Principal investigator 1 Ocular Therapeutix, Inc. $6,494.00 11/21/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235164
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,004.75 11/17/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815744
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,116.00 11/13/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815742
Principal investigator 1 Apellis Pharmaceuticals, Inc. $15,600.00 11/12/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio No dispute reported 06/30/2026 1250363340
Principal investigator 1 Ocular Therapeutix, Inc. $59.64 11/12/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235160
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,437.15 11/11/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815740
Principal investigator 1 Ocular Therapeutix, Inc. $4,964.64 11/05/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235156
Principal investigator 1 Astellas Pharma Global Development $575.00 11/03/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183845
Principal investigator 1 Astellas Pharma Global Development $575.00 11/03/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183847
Principal investigator 1 Astellas Pharma Global Development $575.00 11/03/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183849
Principal investigator 1 Astellas Pharma Global Development $575.00 11/03/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183855
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775081
Principal investigator 1 Ocular Therapeutix, Inc. $5,266.00 10/29/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235148
Principal investigator 1 Ocular Therapeutix, Inc. $17,545.00 10/29/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235152
Principal investigator 1 Astellas Pharma Global Development $50.00 10/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183853
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 10/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775085
Principal investigator 1 Ocular Therapeutix, Inc. $1,045.16 10/15/2025 Non-covered Recipient Entity
Mississippi Retina Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234941
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/13/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235211
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $44,815.00 10/10/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815726
Principal investigator 1 Ocular Therapeutix, Inc. $3,078.00 10/08/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235145
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775079
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,144.00 10/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815736
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $425.00 10/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815738
Principal investigator 1 Apellis Pharmaceuticals, Inc. $5,000.00 09/26/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio No dispute reported 06/30/2026 1250363338
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 09/24/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775101
Principal investigator 1 Boehringer Ingelheim International GmbH $279.72 09/24/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775103
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 09/24/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775105
Principal investigator 1 Boehringer Ingelheim International GmbH $2.10 09/24/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775107
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 09/24/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775109
Principal investigator 1 Ocular Therapeutix, Inc. $5,670.00 09/24/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235140
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,025.00 09/19/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815728
Principal investigator 1 Ocular Therapeutix, Inc. $4,266.00 09/12/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235137
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,175.00 09/10/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815724
Principal investigator 1 Astellas Pharma Global Development $200.00 09/05/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183827
Principal investigator 1 Astellas Pharma Global Development $800.00 09/05/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183829
Principal investigator 1 Ocular Therapeutix, Inc. $73.08 09/05/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235125
Principal investigator 1 Ocular Therapeutix, Inc. $540.00 09/05/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235129
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 09/05/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235133
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,654.00 09/04/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220815766
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $338.00 09/03/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815730
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.00 09/03/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815732
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $406.00 09/03/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815734
Principal investigator 1 Ocular Therapeutix, Inc. $135.00 09/03/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235108
Principal investigator 1 Ocular Therapeutix, Inc. $2,482.36 09/03/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235112
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 09/03/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235117
Principal investigator 1 Ocular Therapeutix, Inc. $2,482.32 09/03/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235121
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775067
Principal investigator 1 Ocular Therapeutix, Inc. $100.66 08/29/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235103
Principal investigator 1 Ocular Therapeutix, Inc. $9,064.00 08/29/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 08/28/2025 Non-covered Recipient Entity
RETINA GROUP INC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232606
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775069
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 08/26/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775071
Principal investigator 1 Boehringer Ingelheim International GmbH $194.88 08/26/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775073
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 08/26/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775075
Principal investigator 1 Boehringer Ingelheim International GmbH $1.22 08/26/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775077
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 08/22/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235094
Principal investigator 1 Ocular Therapeutix, Inc. $135.38 08/22/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235098
Principal investigator 1 Astellas Pharma Global Development $1,850.00 08/20/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183833
Principal investigator 1 Astellas Pharma Global Development $1,850.00 08/20/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183837
Principal investigator 1 Astellas Pharma Global Development $1,850.00 08/20/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183839
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $406.00 08/19/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815714
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,000.00 08/19/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815716
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $406.00 08/18/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815718
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $595.00 08/18/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815720
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $83,585.00 08/18/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815722
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $312.00 08/15/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220815764
Principal investigator 1 Ocular Therapeutix, Inc. $69.44 08/06/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235083
Principal investigator 1 Ocular Therapeutix, Inc. $16,803.00 08/06/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235087
Principal investigator 1 Ocular Therapeutix, Inc. $9,518.00 08/06/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235092
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775065
Principal investigator 1 Ocular Therapeutix, Inc. $5,670.00 07/30/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235080
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 07/26/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815712
Principal investigator 1 Ocular Therapeutix, Inc. $2,482.32 07/18/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235076
Principal investigator 1 Ocular Therapeutix, Inc. $45.78 07/16/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235072
Principal investigator 1 Ocular Therapeutix, Inc. $135.38 07/11/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235068
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 07/10/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815708
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $812.00 07/10/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815710
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 07/09/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235064
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,300.00 07/08/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220815768
Principal investigator 1 Ocular Therapeutix, Inc. $7,540.60 07/02/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235057
Principal investigator 1 Ocular Therapeutix, Inc. $8,505.00 07/02/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235061
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775063
Recipient Ocular Therapeutix, Inc. $10,650.00 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229346
Principal investigator 1 Astellas Pharma Global Development $1,000.00 06/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183825
Principal investigator 1 Astellas Pharma Global Development $9,000.00 06/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183831
Principal investigator 1 Astellas Pharma Global Development $100.00 06/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234183835
Principal investigator 1 Ocular Therapeutix, Inc. $33.00 06/23/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235037
Principal investigator 1 Ocular Therapeutix, Inc. $43.96 06/23/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235041
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $149.96 06/19/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220815762
Principal investigator 1 Ocular Therapeutix, Inc. $7,273.00 06/18/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235034
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.00 06/12/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815706
Principal investigator 1 Ocular Therapeutix, Inc. $2,482.32 06/11/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235030
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,050.00 06/10/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815704
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.00 06/06/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815700
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,688.00 06/06/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815702
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 06/06/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235023
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 06/06/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235026
Principal investigator 1 Ocular Therapeutix, Inc. $135.38 06/04/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235018
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775047
Principal investigator 1 Boehringer Ingelheim International GmbH $19.00 05/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775049
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 05/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775051
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 05/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775053
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 05/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775055
Principal investigator 1 Boehringer Ingelheim International GmbH $104.40 05/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775057
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 05/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775059
Principal investigator 1 Boehringer Ingelheim International GmbH $3.05 05/27/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775061
Principal investigator 1 Ocular Therapeutix, Inc. $2,482.32 05/23/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234998
Principal investigator 1 Ocular Therapeutix, Inc. $1,922.00 05/23/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235002
Principal investigator 1 Ocular Therapeutix, Inc. $5,670.00 05/23/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235006
Principal investigator 1 Ocular Therapeutix, Inc. $214.34 05/23/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235010
Principal investigator 1 Ocular Therapeutix, Inc. $14,004.00 05/23/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235014
Principal investigator 1 Ocular Therapeutix, Inc. $407.83 05/21/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234990
Principal investigator 1 Ocular Therapeutix, Inc. $1,809.50 05/21/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234994
Principal investigator 1 Roche TCRC, Inc. $9,900.00 05/13/2025 Non-covered Recipient Entity
Mississippi Retina Associates PLLC
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211626217
Principal investigator 1 Ocular Therapeutix, Inc. $1,449.00 05/09/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234982
Principal investigator 1 Ocular Therapeutix, Inc. $26.08 05/09/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234986
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775045
Principal investigator 1 Ocular Therapeutix, Inc. $5,670.00 04/30/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234969
Principal investigator 1 Ocular Therapeutix, Inc. $5,130.00 04/30/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234974
Principal investigator 1 Ocular Therapeutix, Inc. $16,628.10 04/30/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234978
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 04/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775093
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 04/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775095
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 04/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775097
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 04/23/2025 Non-covered Recipient Entity
Mississippi Retina Associates
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220775099
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,750.00 04/19/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815696
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 04/18/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234965
Principal investigator 1 Roche TCRC, Inc. $3,802.00 04/18/2025 Non-covered Recipient Entity
Mississippi Retina Associates PLLC
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211626212
Principal investigator 1 Roche TCRC, Inc. $688.50 04/17/2025 Non-covered Recipient Entity
Mississippi Retina Associates PLLC
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211626221
Principal investigator 1 Ocular Therapeutix, Inc. $128.00 04/16/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234961
Principal investigator 1 Ocular Therapeutix, Inc. $3,500.00 04/04/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234958
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.30 04/03/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220815698
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775043
Principal investigator 1 Ocular Therapeutix, Inc. $5,670.00 03/26/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235052
Principal investigator 1 Boehringer Ingelheim International GmbH $7.44 03/25/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775039
Principal investigator 1 Ocular Therapeutix, Inc. $7,000.00 03/14/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235048
Principal investigator 1 Ocular Therapeutix, Inc. $47,466.00 03/07/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235044
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775025
Principal investigator 1 Ocular Therapeutix, Inc. $5,670.00 02/26/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234954
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 02/25/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775027
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775029
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775031
Principal investigator 1 Boehringer Ingelheim International GmbH $85.84 02/25/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775033
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 02/25/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775035
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 02/25/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775037
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775023
Principal investigator 1 Ocular Therapeutix, Inc. $5,670.00 01/24/2025 Non-covered Recipient Entity
MISSISSIPPI RETINA ASSOCIATES PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234950
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Mississippi Retina Associates
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220775041

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2022 Amount invested $0.00 1
PY2022 Value of interest $8,333.33 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $8,333.33 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $8,333.33 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $8,333.33 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2019–2022

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2022 US Retina LLC $0.00 $8,333.33 Shares Physician Covered Recipient No dispute reported 06/30/2026 951870009
PY2021 US Retina LLC $0.00 $8,333.33 Shares Physician Covered Recipient No dispute reported 06/30/2026 856669201
PY2020 US Retina LLC $0.00 $8,333.33 Shares Physician Covered Recipient No dispute reported 06/30/2026 714311493
PY2019 US Retina LLC $0.00 $8,333.33 Shares Physician Covered Recipient No dispute reported 06/30/2026 655843189